ClinicalTrials.gg
CompletedNCT05826613Updated Nov 17, 2026

Respiratory Registry for Lung Health: a Prospective, Observational Study on Adult Patients With Asthma or COPD

An observational study in Chronic Obstructive Pulmonary Disease and Asthma, sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. Completed at 4 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Observational

How we know

Updated Nov 17, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy — 42 open to participants now, 48 under way, 8 of them phase 3. Pulmonary Disease, Chronic Obstructive · Italy.

Enrollment
19th of 68
500 · median 238
Started
2019
with 14 others
Observational
68 of 280
14 open now
Registered
233rd of 280
by date

Among the 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy, this one is the 19th largest by enrollment of the 68 observational ones that give a count, is one of 15 that started in 2019, is one of 68 observational ones, and was the 233rd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

42 of the 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy, or all of them as a file.
02

Study summary

The database will contain a wide range of demographic, clinical, radiological, laboratory, functional, microbiological, treatment, and clinical outcomes data on adults with chronic obstructive pulmonary disease (COPD) and asthma enrolled during stable state with annual follow-up (either one or two-year follow up).

Primary Objective: To collect clinical (including quality of life measurements), laboratory (including non-invasive measurement of biomarkers), microbiological, radiological, functional, treatment variables and clinical outcomes, in adult patients with either asthma or COPD during stable state.

Secondary Objectives: To identify genetic and other omics patterns to develop phenotype handprints for adults with either asthma or COPD. To characterize the airways microbiome in stable patients with either asthma or COPD and identify correlation with clinical phenotypes and/or endotypes.

Read the detailed description

Currently, the World Health Organization estimates that chronic obstructive pulmonary disease (COPD) affects 65 million individuals worldwide and asthma affects 235 million. (World Health Organization. Chronic respiratory diseases. URL: http://www.who.int/respiratory/en/). In 2015, mortality from COPD exceeded 3 million deaths, while mortality from asthma included approximately 400 000 deaths (1). Unquestionably, COPD and asthma pose a significant global burden to which many of our healthcare resources are devoted.

COPD pathology is thought to be primarily due to inflammation. However, Eapen et al.(2) found a reduction in total cellularity in both large (endobronchial biopsies) and small airways (resected lung tissues) with a corresponding reduction in key innate inflammatory cell populations in mild-moderate COPD patients. Colonizing microbes were also found to contribute to pathogenesis, with a possible mechanism through perpetuation of negative immune responses over time (3).

Although cigarette smoking is the most significant risk factor, only a fraction of smokers develops COPD, so genetic associations should also be considered when assessing potential risk factors. The knowledge of the pathogenic mechanisms and genetic bases of respiratory diseases is fundamental for the correct setting of pharmacological and non-pharmacological management. If we consider the main respiratory diseases (COPD, asthma, idiopathic pulmonary fibrosis) but also the so-called rare diseases (e.g. cystic fibrosis), it is evident that both the expression of the disease and the response to treatment are very different among patients. Recent evidences have shown that these responses are related to different genetic models. Decision-making in medical care for decades has often relied on a "one-size-fits-all" approach that applies mean-effect-size results from studies to individual patients. The goal of precision medicine, in contrast, is to allow for more accurate treatment and prevention, decisions based on matching a patient's exposure, lifestyle and biological profile to that of similar patients with measured outcomes. It could be reasonable to hypothesize that mutations in genes which are involved in other respiratory diseases (such as primary ciliary dyskinesia or cystic fibrosis) might be present also in patients with either asthma or COPD. These mutations might alter the function of specific proteins (such as the cystic fibrosis transmembrane conductance regulator protein) and, thus, contribute to the pathophysiology of asthma or COPD. The goal of many "-omics" studies thus far has been to build a knowledgebase of omic variation using single-technology approaches that will help enable precision medicine by providing reference data to identify groups of individuals who share various attributes. In addition to collecting omics data, the application of sophisticated algorithms and use of extensive computational resources to integrate datasets are required to fully characterize diverse patients. The Respiratory Registry project aims to describe the epidemiology of chronic respiratory diseases, including COPD and Asthma, in the cities of Milan, Bergamo and Rome, to define different clinical phenotypes of these diseases, the relative genetic models and the endotypic expression, and then propose new therapeutic approaches, through the implementation of a clinical registry and an enlarged genetic study.

A database of respiratory diseases would have many important functions including but not limited to: 1) Analysis and evaluation of current standard operating procedures in different centres in Milan, Bergamo and Rome in order to compare them with recommendations of the international guidelines and with those used in other countries; 2) Analysis and assessment of differences in the management of adult patients by various professionals in the different centres in order to identify any area of improvement and/or the need to perform further clinical or translation studies; 3) Analysis and evaluation of several factors of disease severity (e.g., recurrence, hospitalization, mortality) that require large amounts of data not obtainable from monocentric studies.

The database will contain a wide range of demographic, clinical, radiological, laboratory, functional, microbiological, treatment, and clinical outcomes data on adults with COPD and asthma enrolled during stable state with annual follow-up (either one or two-year follow up). The database will be developed at the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano and managed by the University Pneumology Unit of this hospital (Promoter of the study). Other University Pneumology Units will be involved, including those from the ASST Santi Paolo e Carlo Hospital in Milan, the ASST Fatebenefratelli-Sacco Hospital in Milan, the IRCCS Policlinico San Donato Hospital in San Donato, Milan, the Papa Giovanni XXIII Hospital in Bergamo and the Respiratory Unit of the Policlinico Gemelli in Rome. Data will be recorded using a case report form (CRF), incorporating all the variables related to the obstructive respiratory diseases identified as relevant for the purpose of this study: COPD and asthma. Study participants will also enter patient follow-up data on an annual basis to provide longitudinal data regarding clinical and therapeutic changes, as well as clinical outcomes. The total study duration will be 3 years, including 2 years for enrollment and at least 1 year of follow-up.

The study will be conducted in accordance with the principles of Good Clinical Practice (GCP). A favourable ethical opinion will be obtained first (as coordinating centre) by the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan and then by each partner site from the appropriate research ethics committee. Furthermore, any other necessary approval required by partner site will be obtained prior to the commencement of the study at that site. All patients must provide written consent to participate in the registry. It is the responsibility of the investigator at each centre to obtain the appropriate local approvals. This prospective observational study will provide important data for the personalised management of obstructive lung diseases. No risk for the patient is foreseen. Informed consent for participation in the study, sample collection and omic analyses will be mandatory.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
  • Asthma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Male or Female aged > 18 years with clinical Diagnosis of either COPD or Asthma.

Asthma and COPD will be defined according to the latest international guidelines (https://goldcopd.org and https://ginasthma.org/2018-gina-report-global-strategy-for-asthmamanagement-and-prevention/)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of prior to any study specific procedures.
  • Male or Female aged > 18 years.
  • Clinical Diagnosis of either or Asthma

Exclusion criteria

Exclusion Criteria:

  • No specific exclusion criteria will be applied to the registry in order to be as adherent as possible to the real-life population
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
500 participants (actual)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • adults with COPD and asthma

    Male or female aged \>18 years with clinical diagnosis of either COPD or asthma.

06

What researchers measure

Primary outcomes

  1. Auscultation of the chest

    A respiratory physical examination, according to the usual care, will be performed and include an assessment of the following: presence of wheeze (yes or no), presence of stridor (yes or no), presence of crackles (yes or no).

    Time frame: 1 year

  2. Presence of dyspnoea (mMRC scale)

    A respiratory physical examination, according to the usual care, will be performed and include an assessment of the presence of dyspnoea. The measurement that will be used to assess this outcome measure is mMRC scale.

    Time frame: 1 year

  3. Forced vital capacity (FVC)

    A complete respiratory functional evaluation will be performed according to the usual care for COPD and Asthma patient. Pulmonary function testing will include: FVC (reported in l)

    Time frame: 1 year

  4. Forced Expiratory Volume in the 1st second (FEV1)

    A complete respiratory functional evaluation will be performed according to the usual care for COPD and Asthma patient. Pulmonary function testing will include: FEV1 (reported in l)

    Time frame: 1 year

  5. Peak expiratory flow (PEF)

    A complete respiratory functional evaluation will be performed according to the usual care for COPD and Asthma patient. Pulmonary function testing will include: PEF(reported in l/min)

    Time frame: 1 year

  6. Vital capacity (VC)

    A complete respiratory functional evaluation will be performed according to the usual care for COPD and Asthma patient. Pulmonary function testing will include: VC (reported in l)

    Time frame: 1 year

  7. Total Lung Capacity (TLC)

    A complete respiratory functional evaluation will be performed according to the usual care for COPD and Asthma patient. Pulmonary function testing will include: TLC (reported in l)

    Time frame: 1 year

  8. Residual Volume (RV)

    A complete respiratory functional evaluation will be performed according to the usual care for COPD and Asthma patient. Pulmonary function testing will include: RV (reported in l)

    Time frame: 1 year

  9. specific airway resistance (SRaw)

    A complete respiratory functional evaluation will be performed according to the usual care for COPD and Asthma patient. Pulmonary function testing will include: sRaw (reported in kPa)

    Time frame: 1 year

  10. specific airway conductance (SGaw)

    A complete respiratory functional evaluation will be performed according to the usual care for COPD and Asthma patient. Pulmonary function testing will include: sGaw (reported in kPa)

    Time frame: 1 year

  11. Diffusing Capacity Of The Lungs For Carbon Monoxide (DLCO)

    A complete respiratory functional evaluation will be performed according to the usual care for COPD and Asthma patient. Pulmonary function testing will include: DLCO.

    Time frame: 1 year

  12. fraction of exhaled NO (FENO)

    A complete respiratory functional evaluation will be performed according to the usual care for COPD and Asthma patient. Pulmonary function testing will include: FeNO.

    Time frame: 1 year

  13. Blood pulse

    The following vital signs will be recorded according to usual care of COPD and Asthma patient: Pulse (recorded in beat per minute)

    Time frame: 1 year

  14. Blood pressure

    The following vital signs will be recorded according to usual care of COPD and Asthma patient: blood pressure (reported in mmHg)

    Time frame: 1 year

  15. body temperature

    The following vital signs will be recorded according to usual care of COPD and Asthma patient: Body temperature (reported in °C)

    Time frame: 1 year

  16. respiratory rate

    The following vital signs will be recorded according to usual care of COPD and Asthma patient: Respiratory Rate (reported in breath per minute)

    Time frame: 1 year

  17. St. George Respiratory Questionnaire

    Quality of life questionnaires will be collected, according to usual care of COPD and asthma patients.

    Time frame: 1 year

  18. Asthma control test (ACT)

    Quality of life questionnaires will be collected, according to usual care of COPD and asthma patients.

    Time frame: 1 year

  19. COPD assessment test (CAT)

    Quality of life questionnaires will be collected, according to usual care of COPD and asthma patients.

    Time frame: 1 year

Secondary outcomes

  1. Collection of biological samples

    The subject's consent to participate in the genetic research components of the study is not mandatory. Two sputum samples, a total of 20 cc of Bronchoalveolar Lavage (BAL), one sample of bronchoaspirate, one slice of lung biopsies, a total of 15 cc of blood, one sample of stool and a total of 15 cc of urine may be collected during routine clinical practice (at the enrolment visit) on stable state. If for any reason the sample will not be drawn at the inclusion visit, it may be taken at any visit until the last study visit. Samples' collection will be performed once per subject during the study and stored locally at each study site and then sent to the Biobank of the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan for storage or to the respiratory Infections Laboratory of the analysis Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan for analysis.

    Time frame: 1 year

07

Study locations

4 sites
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    Milan, MI 20122, Italy
  • Ospedale Papa Giovanni XXIII
    Bergamo, Italy
  • Ospedale Luigi Sacco, Milano
    Milan, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
08

References and documents

Publications

  • GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017 Sep;5(9):691-706. doi: 10.1016/S2213-2600(17)30293-X. Epub 2017 Aug 16. PubMed 28822787 ↗
  • Eapen MS, McAlinden K, Tan D, Weston S, Ward C, Muller HK, Walters EH, Sohal SS. Profiling cellular and inflammatory changes in the airway wall of mild to moderate COPD. Respirology. 2017 Aug;22(6):1125-1132. doi: 10.1111/resp.13021. Epub 2017 Mar 22. PubMed 28326668 ↗
  • Leung JM, Tiew PY, Mac Aogain M, Budden KF, Yong VF, Thomas SS, Pethe K, Hansbro PM, Chotirmall SH. The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD. Respirology. 2017 May;22(4):634-650. doi: 10.1111/resp.13032. Epub 2017 Mar 25. PubMed 28342288 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Jul 2023, 46 months.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's 46 months is above that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion May 2024 → Jul 2023 and completion May 2024 → Jul 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2023
First posted
Apr 24, 2023
StartActual
Sep 10, 2019
Primary completionActual
Jul 31, 2023was May 2024
CompletionActual
Jul 4, 2025was May 2024
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 17, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Italy)
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico · Milan, Italy
  • Ospedale Luigi Sacco, Milano · Milan, Italy
Show 2 removed
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico · Milano, Italy
  • Ospedale Luigi Sacco, Milano · Milano, Italy
Nov 17, 2026
Primary completion
May 31, 2024→Jul 31, 2023 (actual)
Nov 17, 2026
Study completion
May 31, 2024→Jul 4, 2025 (actual)
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Status unknown→Completed
    2 sites added, 2 sites removed
    Show 2 added (2 Italy)
    • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico · Milan, Italy
    • Ospedale Luigi Sacco, Milano · Milan, Italy
    Show 2 removed
    • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico · Milano, Italy
    • Ospedale Luigi Sacco, Milano · Milano, Italy
    Primary completion May 31, 2024→Jul 31, 2023 (now actual)
    Study completion May 31, 2024→Jul 4, 2025 (now actual)
    + 3 other changes: verification date, contact details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05826613
Responsible party
Sponsor
First posted
Apr 24, 2023
Start date
Sep 10, 2019
Primary completion
Jul 31, 2023
Completion
Jul 4, 2025
Last update
Nov 17, 2026

Study contacts

Francesco Blasi, Prof.
principal investigator · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion